• 1
    Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979; 77: 84769.
  • 2
    Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984; 86: 24966.
  • 3
    Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993; 34: 24751.
  • 4
    Jackson LM, O'Gorman PJ, O'Connell J, et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. Q J Med 1997; 90: 1838.
  • 5
    Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterol 1998; 93: 4428.
    Direct Link:
  • 6
    Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998; 10: 4113.
  • 7
    Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. North American Azathioprine Study Group. Gastroenterology 1999; 117: 52735.
  • 8
    Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998; 114: 115160.
  • 9
    Feagan BG. Aminosalicylates for active disease and in the maintenance of remission in Crohn’s disease. Eur J Surg 1998; 164: 9039.DOI: 10.1080/110241598750005066
  • 10
    Shaffer JA, Williams SE, Turnberg LA, et al. Absorption of prednisolone in patients with Crohn’s disease. Gut 1983; 24: 1826.
  • 11
    Shepherd HA, Barr GD, Jewell DP. Use of an intravenous steroid regimen in the treatment of acute Crohn’s disease. J Clin Gastroenterol 1986; 8: 1549.
  • 12
    Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 83641.
  • 13
    Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease [see comments]. N Engl J Med 1994; 331: 8425.
  • 14
    Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut 1997; 41: 20914.
  • 15
    Sartor RB. Microbial factors in the pathogenesis of Crohn’s disease, ulcerative colitis and experimental intestinal inflammation. In: Kirsner JB, Shorter RG, eds. Inflammatory Bowel Disease, 4th edn. Baltimore: Williams & Wilkins, 1995: 96–124.
  • 16
    Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. II. Result. Gastroenterology 1982; 83: 55062.
  • 17
    Sutherland LR, Singleton J, Sessions J, et al. Double-blind placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991; 32: 10715.
  • 18
    Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 32832.
  • 19
    Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn’s disease. Can J Gastroenterol 1998; 12: 536.
  • 20
    Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995; 108: 161721.
  • 21
    Gionchetta P & Campieri M. Probiotic therapy. In: Jewell D, ed. IBD, Salicylates and Other Relevant Therapies. London: Wells Medical, 2000: 111–6.
  • 22
    Gonzalez-Huix F, Leon R, Fernandez-Banares F, et al. Polymeric enteral diets as primary treatment of active Crohn’s disease: a prospective steroid controlled trial. Gut 1993; 34: 77882.
  • 23
    Giaffer MH, North G, Holdsworth CD. Controlled trial of polymeric versus elemental diet in treatment of active Crohn’s disease [see comments]. Lancet 1990; 335: 8169.
  • 24
    Verma S, Brown S, Kirkwood B, et al. Polymeric versus elemental diet as primary treatment in active Crohn’s disease: a randomized, double-blind trial. Am J Gastroenterol 2000; 95: 7359.
    Direct Link:
  • 25
    Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology 1995; 108: 105667.
  • 26
    Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn’s disease. Gut 1996; 38: 5438.
  • 27
    Matsui T, Ueki M, Yamada M, et al. Indications and options of nutritional treatment for Crohn’s disease. A comparison of elemental and polymeric diets. J Gastroenterol 1995; 30(Suppl. 8): 957.
  • 28
    Ferguson A, Glen M, Ghosh S. Crohn’s disease: nutrition and nutritional therapy. Baillieres Clin Gastroenterol 1998; 12: 93114.
  • 29
    Riordan AM, Hunter JO, Cowan RE, et al. Treatment of active Crohn’s disease by exclusion diet: East Anglian multicentre controlled trial [see comments]. Lancet 1993; 342: 11314.
  • 30
    Fernandez-Banares F, Cabre E, Esteve-Comas M, et al. How effective is enteral nutrition in inducing clinical remission in active Crohn’s disease? A meta-analysis of the randomized clinical trials. J Parenter Enteral Nutr 1995; 19: 35664.
  • 31
    Messori A, Trallori G, D'Albasio G, et al. Defined-formula diets versus steroids in the treatment of active Crohn’s disease: a meta-analysis. Scand J Gastroenterol 1996; 31: 26772.
  • 32
    Gorard DA, Hunt JB, Payne-James JJ, et al. Initial response and subsequent course of Crohn’s disease treated with elemental diet or prednisolone. Gut 1993; 34: 1198202.
  • 33
    Miura S, Tsuzuki Y, Hokari R, et al. Modulation of intestinal immune system by dietary fat intake: relevance to Crohn’s disease. J Gastroenterol Hepatol 1998; 13: 118390.
  • 34
    O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet 1978; 2: 9557.
  • 35
    Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 9817.
  • 36
    Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 13242.
  • 37
    Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 1993; 105: 36772.
  • 38
    Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995; 37: 6748.
  • 39
    Sandborn WJ, Sutherland L, Pearson D, et al. Azathioprine or 6-Mercaptopurine for Inducing Remission of Crohn’s Disease, CD-ROM, Issue 2. Oxford: The Cochrane Library, 1999.
  • 40
    Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 2159.
  • 41
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995; 332: 2927.
  • 42
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. . The North American Crohn’s Study Group Investigators. N Engl J Med 2000; 342: 162732.
  • 43
    Targan SR, Van Hanauer SB, Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 44
    D'Haens G, Deventer S, Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999; 116: 102934.
  • 45
    Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999; 116: 228.
  • 46
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 7619.
  • 47
    Hassard PV, Vasiliauskas EA, Kam LY, et al. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn’s disease. Inflamm Bowel Dis 2000; 6: 1620.
  • 48
    Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial Investigators. N Engl J Med 1994; 330: 184651.
  • 49
    Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn’s disease: a 12-month study. The European Study Group. Gastroenterology 1995; 109: 77482.
  • 50
    Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1995; 109: 77482.
  • 51
    Ierardi E, Principi M, Rendina M, et al. Oral tacrolimus (FK 506) in Crohn’s disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000; 30: 2002.DOI: 10.1006/cryo.1993.1020
  • 52
    Alexander-Williams J. Inflammatory bowel disease revisited: surgery today and tomorrow. Scand J Gastroenterol 1990; 175(Suppl.): 10712.
  • 53
    Andrews HA, Lewis P, Allan RN. Prognosis after surgery for colonic Crohn’s disease. Br J Surg 1989; 76: 118490.
  • 54
    Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg 1996; 224: 56371.DOI: 10.1006/jsvi.1999.2224
  • 55
    Kim NK, Senagore AJ, Luchtefeld MA, et al. Long-term outcome after ileocecal resection for Crohn’s disease. Am Surg 1997; 63: 62733.
  • 56
    Pearson DC, May G, Fick G, et al. Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Ann Intern Med 1995; 123: 13242.
  • 57
    Lowry PW, Weaver AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis 1999; 5: 23945.
  • 58
    Present DH & Lichtiger S. Efficacy of cyclosporin in treatment of fistula in Crohn’s disease. Dig Dis Sci 1994; 39: 37480.
  • 59
    Jakobovits J & Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 1984; 79: 53340.
  • 60
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398405.
  • 61
    Wolff BG, Culp CE, Beart RW, et al. Anorectal Crohn’s disease. A long-term perspective. Dis Colon Rectum 1985; 28: 70911.
  • 62
    Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 146573.
  • 63
    Caprilli R, Corrao G, Taddei G, et al. Prognostic factors for postoperative recurrence of Crohn’s disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Dis Colon Rectum 1996; 39: 33541.
  • 64
    McLeod RS. Is it possible to prevent recurrent Crohn’s disease with medical or surgical interventions? Neth J Med 1996; 48: 6870.DOI: 10.1016/0300-2977(95)00089-5
  • 65
    Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology 2000; 118: 26473.
  • 66
    Sutherland LR. Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there? Gastroenterology 2000; 118: 4368.
  • 67
    Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut 2000; 46(Suppl. 1): i18.
  • 68
    Pearson DC, May GR, Fick G, et al. Azathioprine for Maintaining Remission of Crohn’s Disease, CD-ROM, Issue 2. Oxford: The Cochrane Library, 1999.
  • 69
    Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 30918.DOI: 10.1016/s0140-6736(97)01300-7
  • 70
    Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology 1998; 114: 114350.
  • 71
    Fraga XF, Vergara M, Medina C, et al. Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 6837.
  • 72
    Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn’s disease. Gastroenterology 1994; 106: 6438.
  • 73
    Cosnes J, Beaugerie C, Carbonnel F, et al. Decreased severity of Crohn’s disease after smoking cessation. Gastroenterology 2000; 118: A4834A4834.
  • 74
    Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 1997; 349: 5214.
  • 75
    Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease. Gastroenterology 1998; 114: 113342.
  • 76
    Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 1997; 113: 3839.